2020, January 16-18: Perplexing Problems in Breast Pathology (and How to Solve Them)
Jan. 16-18, 2020 - Palm Springs, California
16 CME / 16 SAMs
This course is designed to eliminate a variety of practice gaps in diagnostic breast pathology. In general, there is a misdiagnosis rate of ~10% in breast biopsies. For some lesions which are notoriously problematic, the misdiagnosis rate is even higher.
Review of the literature and the faculty’s clinical experience as consultant breast pathologists have clearly documented areas in breast pathology that remain diagnostic problems even for experienced pathologists. These include the categorization of proliferative breast lesions, the classification of in situ lesions, papillary lesions, fibroepithelial lesions, spindle cell lesions, vascular lesions, the distinction between invasive and in situ lesions, and the proper classification of a variety of uncommon benign and malignant lesions. In addition, with the frequent use of core needle biopsy of non-palpable breast lesions, pathologists are often faced with the challenge of distinguishing these entities on small specimen samples.
This interactive microscopy course attempts to eliminate diagnostic error by highlighting pitfalls and the approaches to resolving them by using routine microscopic examination of H and E-stained sections and immunostains. The role of newer adjunctive molecular tests will also be discussed where appropriate.
This course will address both medical knowledge and competence with the goal of improving clinical practice.
- Evaluate diagnostic criteria and clinical significance of various common and uncommon benign, in situ and malignant lesions of the breast in both core needle biopsy specimens and surgical specimens
- Describe the differential diagnostic problems encountered in breast pathology and develop strategies to resolve them in your practice environment
- Utilize the latest information on the uses and limitations of immunohistochemistry in resolving diagnostic problems in breast pathology
- Stuart J. Schnitt, MD
Dana-Farber/Brigham and Women’s Cancer Center;
Harvard Medical School
- Edi Brogi, MD, PhD
Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College
- Ashley Cimino-Mathews, MD
Johns Hopkins University School of Medicine
- J. Jordi Rowe, MD
CONTINUING MEDICAL EDUCATION AND CONTINUING CERTIFICATION
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this live activity for a maximum of 16 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Continuing Certification (CC). Physicians can earn a maximum of 16 SAM credit hours.
USCAP records courses at the Interactive Learning Center for future educational purposes. By registering for this course, you consent that your likeness may be used by USCAP.
Cancellations will be assessed an administrative charge of 25% of the total registration fee. There will be no refunds for cancellations within 14 days of the event. The Academy is not responsible for travel expenses incurred as a result of an event cancellation.